Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Prostate Biomarkers with Reference to Body Mass Index and Duration of Prostate Cancer

  • Poudel, Bibek (Department of Biochemistry, Manipal College of Medical Sciences) ;
  • Mittal, Ankush (Department of Biochemistry, Nepalese Army Institute of Health Sciences) ;
  • Shrestha, Rojeet (Department of Biochemistry, Nepal Medical College) ;
  • Nepal, Ashwini Kumar (Department of Biochemistry, BP Koirala Institute of Health Sciences) ;
  • Shukla, Pramod Shanker (Department of Biochemistry, Manipal College of Medical Sciences)
  • Published : 2012.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: This study was performed to assess prostate biomarkers with reference to body mass index and duration of prostate cancer. Materials and Methods: A hospital based retrospective study was undertaken using data retrieved from the register maintained in the Department of Biochemistry of Manipal Teaching Hospital, Pokhara, Nepal between $1^{st}$ January, 2009 and $28^{th}$ February, 2012. Biomarkers studied were prostate specific antigen (PSA), acid phosphatase (ACP) and prostatic acid phosphatase (PAP), alkaline phosphatase (ALP) and gamma glutamyl transpeptidase (${\gamma}GT$). Demographic data including age, duration of disease, body weight, height and body mass index (BMI) were also collected. Duration of disease was categorized into three groups: <1 year, 1-2years and >2 years. Similarly, BMI ($kg/m^2$) was categorized into three groups: <23 $kg/m^2$, 23-25 $kg/m^2$ and >25 $kg/m^2$. Descriptive statistics and testing of hypothesis were used for the analysis using EPI INFO and SPSS 16 software. Results: Out of 57 prostate cancers, serum level of PSA, ACP and PAP were increased above the cut-off point in 50 (87.5%), 30 (52.63%) and 40 (70.18%) respectively. Serum levels of PSA, ACP and PAP significantly declined with the duration of disease after diagnosis. We observed significant and inverse relation between PSA and BMI. Similar non-signficiant tendencies were apparent for ACP and PAP. Conclusions: Decreasing levels of prostate biomarkers were found with the duration of prostate cancer and with increased BMI. Out of prostate biomarkers, PSA was found to be significantly decreased with the duration of disease and BMI.

Keywords

References

  1. Andersson SO, Wolk A, Bergstrom R, et al (1997). Body size and prostate cancer: a 20-year follow-up study among 135,006 Swedish construction workers. J Natl Cancer Inst, 89, 385-9. https://doi.org/10.1093/jnci/89.5.385
  2. Angelis GD, Rittenhouse HG, Mikolajczyk SD, et al (2007). Twenty years of PSA: from prostate antigen to tumor marker. Rev Urol, 9, 113-23.
  3. Bauer HW (1988). Acid phosphatase, alkaline phosphatase and prostate - specific antigen: usefulness in diagnosis of metastatic disease and follow-up. Prog Clin Biol Res, 269, 33-42.
  4. Ceber E, Şimşir A, Umar DÇ, et al (2010). Prevalence of prostate cancer among men aged 40+ living in Osman Gazi health care district. Asian Pac J Cancer Prev, 11, 473-8.
  5. Chiu PK, Wong AY, Hou SM, et al (2011). Effect of body mass index on serum prostate-specific antigen levels among patients presenting with lower urinary tract symptoms. Asian Pac J Cancer Prev, 12, 1937-40.
  6. Filella X, Molina R, Jo J, et al (1990). Clinical usefulness of prostate-specific antigen and prostatic acid phosphatase in patients with prostatic cancer. Tumour Biol, 11, 289-94. https://doi.org/10.1159/000217664
  7. Freeman MR, and Solomon KR (2004). Cholesterol and prostate cancer. J Cell Biochem, 91, 54-69. https://doi.org/10.1002/jcb.10724
  8. Kuriyama M, Wang, MC, Papsidero LD, et al (1980). Quantitation of Prostate-Specific Antigen in Serum by a Sensitive Enzyme Immunoassay. Cancer Res, 40, 4658-62.
  9. McGrowder DA, Jackson LA, Crawford TV (2012). Prostate Cancer and Metabolic Syndrome: Is there a link? Asian Pac J Cancer Prev, 13, 1-13. https://doi.org/10.7314/APJCP.2012.13.1.001
  10. Mittal A, Sathian B, Chandrasekharan N, et al (2011). Role of hypercholesterolemia in prostate cancer--case control study from Manipal Teaching Hospital Pokhara, Nepal. Asian Pac J Cancer Prev, 12, 1905-7.
  11. Morote RJ, de Torres MJA (1989). Determination of prostatic specific antigen and prostatic acid phosphatase as tumour markers of cancer of the prostate. Arch Esp Urol, 42, 124-30.
  12. Moss DW, Henderson A, Kachmar JF (1987). Enzymes. In 'Fundamentals of Clinical Chemistry', Eds Tietz NW, WB Saunders Co, Philadelphia pp310-3, 329-32.
  13. Nath A, Singh JK, Vendan SE, et al (2012). Elevated level of prostate specific antigen among prostate cancer patients and high prevalence in the Gangetic zone of Bihar, India. Asian Pac J Cancer Prev, 13, 221-3. https://doi.org/10.7314/APJCP.2012.13.1.221
  14. Presti JC Jr, Lee U, Brooks JD, et al (2004). Lower body mass index is associated with a higher prostate cancer detection rate and less favorable pathological features in a biopsy population. J Urol, 171, 2199-202. https://doi.org/10.1097/01.ju.0000124847.82541.60
  15. Schuurman AG, Goldbohm RA, Dorant E, et al (2000). Anthropometry in relation to prostate cancer risk in the Netherlands Cohort Study. Am J Epidemiol, 151, 541-9. https://doi.org/10.1093/oxfordjournals.aje.a010241
  16. Sfoungaristos S, Perimenis P (2011). Implications of PSA kinetics for an adverse pathology after radical prostatectomy. Asian Pac J Cancer Prev, 12, 1765-9.
  17. Wajsman Z, Chu TM, Bross D, et al (1978). Clinical significance of serum alkaline phosphatase isoenzymes levels in advanced prostate carcinoma. J Urol, 119, 244-6. https://doi.org/10.1016/S0022-5347(17)57446-7

Cited by

  1. Utility of Digital Rectal Examination, Serum Prostate Specific Antigen, and Transrectal Ultrasound in the Detection of Prostate Cancer: A Developing Country Perspective vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3087
  2. Dietary carrot consumption and the risk of prostate cancer vol.53, pp.8, 2014, https://doi.org/10.1007/s00394-014-0667-2